Carla Y. Vossen

Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/refractory multiple myeloma treated in Europe

M. Cavo, Fredrik Schjesvold, Meletios Dimopoulos, Michel Delforge et autres

Not available.

it, no, gr, be, es, us, at, gb, ch (code pays fourni par la source)

Evaluation of Long-Term Disease Modification with Belimumab (BEL) in Routine Care of Patients (Pts) with Lupus Nephritis (LN): The OBSErve-LN Study

Keiju Hiromura, Julia Weinmann‐Menke, Enrique Morales, Brad H. Rovin et autres

Background: In LN, the treatment goal of disease modification is indicated by preserved kidney function and end-stage kidney disease prevention >5 years after treatment. BEL was approved for active LN following the 2-year BLISS-LN trial (NCT01639339), which demonstrated significant kidney outcome improvements. …

jp, de, es, us, cn, in, gb (code pays fourni par la source)

REIMAGINE: A prospective real-world evaluation of clinical remission in patients with severe asthma treated with mepolizumab in a timely manner

Florence Schleich, Peter Hugo Howarth, Lisette Delgado Sanchez, Francesca Puggioni et autres

Background: Clinical remission (CR) in severe asthma (SA) is an ambitious and achievable treatment goal; further prospective real-world analyses are needed to determine the impact of timely intervention on achieving CR. Aims: REIMAGINE prospectively evaluates the proportion of a subset of patients …

be, it, ca, es, us, nl (code pays fourni par la source)

Mepolizumab Effectiveness in Severe Asthma With/Without Chronic Rhinosinusitis With Nasal Polyps: Real‐World Pooled Analysis

Florence Schleich, Stelios Loukides, Rekha Chaudhuri, Jörg D. Leuppi et autres

BACKGROUND: Severe asthma with an eosinophilic phenotype (SAEP) and chronic rhinosinusitis with nasal polyps (CRSwNP) are predominantly type 2-driven diseases, characterised by eosinophilic inflammation and substantial disease burden. Mepolizumab, a humanised monoclonal antibody that targets interleukin-5, a key cytokine in type 2 …

be, gr, gb, ch, it, es (code pays fourni par la source)

Real-world effectiveness of mepolizumab in patients with severe asthma with/without chronic rhinosinusitis with nasal polyps: pooled analysis from European cohorts

Inés Palomares, Stelios Loukides, Florence Schleich, Rekha Chaudhuri et autres

Background: Patients with severe asthma and an eosinophilic phenotype (SAEP) with comorbid chronic rhinosinusitis with nasal polyps (CRSwNP) typically have high NP recurrence rates and poor asthma control. There remains limited evidence on the effectiveness of mepolizumab in patients with SAEP with/without …

es, gr, be, gb, ch, it, nl (code pays fourni par la source)

P-421 Characteristics of Patients and Management of Ocular Adverse Events After Treatment With Belantamab Mafodotin (Belamaf) in Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Study in Europe

Michèle Cavo, Michel Delforge, Meletios Athanasios Dimopoulos, Fernando Escalante et autres

P-238 A real-world observational study of belantamab mafodotin (belamaf) as a treatment for relapsed/ refractory multiple myeloma (RRMM)

Michèle Cavo, Michel Delforge, Meletios Athanasios Dimopoulos, Fernando Escalante et autres

Varying Willingness to Pay Based on Severity of Illness: Impact on Health Technology Assessment Outcomes of Inpatient and Outpatient Drug Therapies in The Netherlands

Marieke Schurer, Suzette M. Matthijsse, Carla Y. Vossen, Marjolijn van Keep et autres

OBJECTIVES: Since 2015, Zorginstituut Nederland (ZIN) has linked disease severity ranges of 0.10 to 0.40, 0.41 to 0.70, and 0.71 to 1.00 with willingness-to-pay (WTP) reference values of €20 000, €50 000, and €80 000 per quality-adjusted life year gained, respectively. We …

gb (code pays fourni par la source)

PMU82 VARYING WILLINGNESS-TO-PAY BASED ON DISEASE BURDEN: IMPACT ON HEALTH TECHNOLOGY ASSESSMENT OUTCOMES OF SPECIALIST DRUGS IN THE NETHERLANDS

Marieke Schurer, Carla Y. Vossen, Marjolijn van Keep, James Horscroft et autres

gb (code pays fourni par la source)

Identification of coagulation gene 3′UTR variants that are potentially regulated by microRNAs

Carla Y. Vossen, Astrid van Hylckama Vlieg, Raúl Teruel‐Montoya, Salam Salloum‐Asfar et autres

MicroRNAs have been recognized as critical regulators of gene expression and might affect the risk of venous thrombosis. We aimed to identify 3' untranslated region (UTR) variants in coagulation genes that influence coagulation factor levels and venous thrombosis risk. The 3'UTR of …

nl, es (code pays fourni par la source)

Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis

Katerina Papadimitropoulou, Carla Y. Vossen, Andreas Karabis, Christina Donatti et autres

OBJECTIVE: Major depressive disorder (MDD) affects about 10-15% of the general population in a lifetime. A considerable number of patients fail to achieve full symptom remission despite adequate treatment and are considered treatment resistant (TRD). The current study compared the relative efficacy …

gb, de (code pays fourni par la source)

Genetic variants in Cell Adhesion Molecule 1 (CADM1): A validation study of a novel endothelial cell venous thrombosis risk factor

Hugoline G. de Haan, Irene D. Bezemer, Carla Y. Vossen, Astrid van Hylckama Vlieg et autres

nl, us (code pays fourni par la source)